Selio System Development and commercialisation of a novel needle tract sealant system for pneumothorax prevention during lung biopsy
- Coordinator
- Selio Medical Limited, Ireland
- Runs
- 1 October 2022 to 30 September 2024
- Status
- Finished
- EU funding
- €2.5m
- Total cost
- €3.7m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 190103391
What the project is doing
In the project's own words, from its summary on CORDIS.
Every 30sec someone somewhere globally dies of lung cancer. EU records ~320,000 pa new lung cancer cases. Early lung cancer diagnosis can save lives through timely/efficient interventions. CT guided lung biopsy is the gold standard for lung cancer screening. However, it comes with 62% inherent risk of life-threatening complication pneumothorax (PTX)- a complete or partial lung collapse. PTX sufferers require further radiological scans, needle aspiration, chest tube insertion or surgery- requiring additional hospital stay & ~€15k cost-of-care.
Currently no method or device prevents PTX during the percutaneous needle access of lung. Our patented Selio System will be world’s first system specifically designed to prevent PTX occurring before biopsy even takes place. Used by an interventional radiologist before lung biopsy procedure in a 2 min ‘add-on’ to the current standard of care, Selio System pre-seals the needle tract in tissue, thereby preventing air & blood leak from those organs
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Selio Medical Limited | Dublin | Ireland | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI